Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) — Stella

Home/Opioid Use Disorder/

View on ClinicalTrials.gov

Recruiting

Back to Opioid Use Disorder trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Yale University, New Haven, Connecticut

Key details

Phase

Early testing

Sponsor

Yale University

Collaborators

National Institute on Drug Abuse (NIDA)

Enrollment target

~12 participants

Started

May 2025

Primary completion

January 2027

Age range

21 Years – 55 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.